- Home
- Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
- Structural Heart Disease
Available Credit:
- 0.50
Course Published On:
Course Expiry Date:
Release / Expiration Date
August 3, 2022 – August 3, 2023
Method of Participation
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Commercial Support
This activity is supported by an educational grant from Bristol Myers Squibb.
Disclosure
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Grants/Research Support: Pfizer, Ionis, Ultomics
Consultant: Bristol Myers Squibb, Eidos
Honoraria: Alnylam, Eidos, Pfizer
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: The use of unlabelled drugs (aficamten and mavacamten) will be discussed.
Staff and Reviewer Disclosures
ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Terms & Conditions
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Target Audience
- Cardiologists
- Heart Failure Specialists
- Other Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
- Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
Speaker
Related Courses
- 1.00
Published:
Learning objectives
- Recall current and predicted trends in TAVI with respect to preserving coronary access
- Consider determining factors for choosing valves in low risk populations
- Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Recall the latest data on durability and clinical outcomes for TAVI
- Understand how TAVI is advancing and become aware of future treatment options for lifetime management of patients with aortic valve disease
- Become more confident using TAVI in cases with complex anatomy
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Compare the utility of repair and replacement valve technology in mitral regurgitation
- Individualise valve choice for aortic regurgitation based on valve durability and patient features
- Recall the utility and limitations of specialty balloons
- Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
- Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
- Identify suitable patients for interatrial shunting
- Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
- 1.00
Published:
Learning objectives
- Describe the challenges with lifetime management in severe AS in both a SAVR and TAVI-first scenario
- Summarise clinical evidence for TAVI in low surgical risk patients
- Recall different guideline recommendations for SAVR and TAVI approaches
- Assimilate current clinical knowledge with patient preferences when formulating treatment plans for severe AS patient
- Not accredited
Published:
Learning objectives
- Recall the latest data showing why durability and hemodynamics matter for initial valve selection
- Discuss the latest techniques to help achieve optimal outcomes for patients with longer life expectancy
- Review TAVI cases that highlight procedure optimisation with the Evolut pro+ platform
- 1.00
Published:
Learning objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
- 1.00
Published:
Learning objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation